Advertisement
Australia markets closed

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • AUD/USD

    0.6528
    +0.0028 (+0.44%)
     

  • OIL

    83.22
    +0.41 (+0.50%)
     

  • GOLD

    2,337.40
    -1.00 (-0.04%)
     

  • Bitcoin AUD

    97,872.72
    -4,325.62 (-4.23%)
     

  • CMC Crypto 200

    1,365.63
    -16.94 (-1.23%)
     

  • AUD/EUR

    0.6084
    +0.0014 (+0.23%)
     

  • AUD/NZD

    1.0946
    +0.0004 (+0.04%)
     

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     

  • FTSE

    8,094.22
    +53.84 (+0.67%)
     

  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     

  • DAX

    18,020.28
    -68.42 (-0.38%)
     

  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

Scout Bio to Present at Wells Fargo 2021 Virtual Healthcare Conference

Scout Bio

PHILADELPHIA, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Scout Bio today announced that Mark Heffernan, Chief Executive Officer, will present at the upcoming Wells Fargo Virtual Healthcare Conference on Thursday, September 9, 2021 at 4:00 p.m. ET.

About Scout Bio
Scout Bio is a biotechnology company revolutionizing pet medicine by delivering a pipeline of one-time gene therapies for major chronic pet health conditions. Scout Bio’s therapeutics are designed to induce long-term expression of therapeutic proteins in pet patients using AAV vector technology. Scout Bio has a research and development collaboration with the University of Pennsylvania’s Gene Therapy Program, a leader in the field of genetic medicine research. Scout Bio is a private company headquartered in Philadelphia, Pennsylvania. For more information, see www.scoutbio.co

For further information, please contact:

Investors:
Sarah McCabe
Stern Investor Relations, Inc.
212.362.1200
sarah.mccabe@sternir.com

Media:
Fran Gaconnier
Scout Bio
212.417.4142
fran.gaconnier@scoutbio.co